News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation

Hypofractionated patients showed similar PSA control and overall survival with nearly three weeks less of radiation therapy

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation

October 31, 2018 — An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with hypofractionated intensity modulated radiation therapy (HIMRT) yields equivalent disease outcomes compared with conventional intensity modulated radiation (CIMRT). It is the largest randomized single-institution study with the longest follow-up period on this topic to date.

The study enrolled 300 men and followed them over a median period of 11 years after treatment. Half had received H-IMRT and half had received C-IMRT. Men in both groups also received standard-of-care androgen deprivation therapy (ADT) when it was indicated. H-IMRT delivers more radiation per treatment session, allowing patients to complete treatment over a much shorter period than C-IMRT (5 ½ weeks versus 8 weeks). Advantages include fewer medical appointments, lower costs and more efficient utilization of clinical resources.

Vladimir Avkshtol, M.D., a radiation oncology resident at Fox Chase, presented the results at an oral session at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 in San Antonio, Texas.

At five years and 10 years after treatment, men who had received either form of therapy showed similar results on several measures, including prostate-specific antigen (PSA) control and overall survival. There was initially some cause for concern over a trend toward higher rate of developing metastases in men in the H-IMRT group; however, this was not statistically significant and no subset of patients seemed to be at higher risk on further analysis.

“Our analysis shows that for most men with localized prostate cancer, H-IMRT is a viable option and should be considered for most men. Our study is one of the biggest and most mature studies of its kind in the U.S.,” said Avkshtol.

Read more about late-breaking clinical trials presented at ASTRO 2018.

For more information: www.astro.org

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...